Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancer. (The PE-PE Study).

NCT05578664 is registered in ClinicalTrials.gov with Consorzio Oncotech as lead sponsor.

NCT NCT05578664
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05578664 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancer. (The PE-PE Study).
Lead sponsor
Consorzio Oncotech
Phase
Phase 2
Overall status
Unknown status
Start date
March 14, 2023
Completion date
October 31, 2025
Enrollment
81 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

oligometastatic renal cell carcinoma